Maxinovel Pharmaceuticals
PrivateLast Round
Series C
Extension
Oct 1, 2022
Est. Valuation
$56M
Total Funding Raised
$41.5M
Company Overview
Maxinovel Pharmaceuticals is a biotechnology company that focuses on the research and development of first-in-class small molecule innovative drugs for oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Maxinovel Pharmaceuticals Comparables
Compare Maxinovel Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 华健未来（成都）科技股份有限公司 | 81% | |
| TechnoDerma Medicines Inc. | 78% | |
| Reistone Biopharma | 78% |
For institutional investors. Book with your work email.
Maxinovel Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Oct 1, 2022 | ||||
| Series C | Jan 4, 2021 | ||||
| Series B | Jul 1, 2019 | ||||
| Series A | Feb 1, 2018 |
For institutional investors. Book with your work email.
Maxinovel Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lapam Capital | Series C Extension |
| Baheal Zhongxin Capital | Series C Extension |
| Share Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2022
$14M round with Baheal Zhongxin Capital and Lapam Capital
- Jan 4, 2021
Raised $28M in Series C funding.
For institutional investors. Book with your work email.
Maxinovel Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Maxinovel Pharmaceuticals's valuation, stock price, and market status.
Is Maxinovel Pharmaceuticals a public or private company?
Maxinovel Pharmaceuticals is a private company.
What is the current stock price of Maxinovel Pharmaceuticals?
Maxinovel Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Maxinovel Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Maxinovel Pharmaceuticals worth (valuation)?
Maxinovel Pharmaceuticals's valuation is estimated at $56.0M based on funding round data.
Can I buy Maxinovel Pharmaceuticals stock?
Maxinovel Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Maxinovel Pharmaceuticals's last funding round?
Maxinovel Pharmaceuticals's most recent funding round was Series C Extension on October 1, 2022.
Who are the main investors in Maxinovel Pharmaceuticals?
Key investors in Maxinovel Pharmaceuticals include Lapam Capital, Baheal Zhongxin Capital, Share Capital.
Will Maxinovel Pharmaceuticals IPO soon?
No public IPO plans have been announced for Maxinovel Pharmaceuticals.
How can I track Maxinovel Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Maxinovel Pharmaceuticals's shares on secondary markets.